Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forest Laboratories has reported net revenues of $1.15bn for the first quarter of fiscal 2012 ended 30 June 2011, an increase of 8.2%, compared to $1.06bn for the same period in 2010.
Subscribe to our email newsletter
The company has reported a net income of $258.14m, or $0.90 per diluted share, compared to net income of $117.48m or $0.39 per diluted share, for the same period last year.
Forest Labs chairman and CEO Howard Solomon said they initiated the scientific launches to health care professionals for their newest products, Daliresp and Viibryd and both products became available to patients in June.
"Daliresp and Viibryd will be formally launched to the medical community next month at the same national sales meeting of all of our salesforces," Solomon said.
"Upon the official launches of Daliresp and Viibryd, we will have launched a total of five products in just three years with three of those products launched in this current calendar year."